Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two RNAi-Related Patent Applications: Mar 22, 2007

Title: Ocular Gene Therapy Using Avalanche-Mediated Transfection
Number: 20070059835
Filed: Aug. 15, 2006
Lead Inventor: Thomas Chalberg, Stanford University
The invention “provides a method of treating an ocular disease in a subject,” the patent application’s abstract states. “In a first step, a nucleic acid is introduced into cells or a tissue. The nucleic acid is introduced by electron avalanche transfection. With this technique, a high electric field induces a vapor bubble and plasma discharge between an electrode and the surrounding medium. The formation of a vapor bubble generates mechanical stress. Plasma discharge through the ionized vapor in the bubble enables connectivity between the electrode and the surrounding medium, so that mechanical stress and electric field are applied simultaneously, which results in permeabilization of the cells or tissue,” the abstract states. “This permeabilization in turn allows the nucleic acid to enter the cell or tissue. Cells or tissue containing the nucleic acid are then transplanted into an ocular region of the subject.”

Title: Methods and Compositions for Inhibiting Viral Infections
Number: 20070060537
Filed: April 28, 2006
Inventor: Yuval Reiss, Proteologics
“The [patent] application relates to inhibitors of POSH-associated E2 enzymes, such as the UBC13/UEV1 complex,” its abstract states. “Methods of using such RNAi inhibitors for treating viral disorders, such as, for example, HIV infection, are also described.”